Retracted: Silencing of cystatin SN abrogates cancer progression and stem cell properties in papillary thyroid carcinoma
Papillary thyroid carcinoma (PTC) accounts for approximately 80% of total thyroid cancers worldwide. Although the prognosis for early‐stage PTC is favorable, the 5‐year survival rate of patients with late‐stage PTC is still very poor. Cystatin SN (cystatin 1, CST1) facilitates the progression of mul...
Main Authors: | Jiaojiao Ding, Xiaorong Wang, Junxi Gao, Tao Song |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2021-08-01
|
Series: | FEBS Open Bio |
Subjects: | |
Online Access: | https://doi.org/10.1002/2211-5463.13221 |
Similar Items
-
Cystatin SN promotes epithelial-mesenchymal transition and serves as a prognostic biomarker in lung adenocarcinoma
by: Jian Yang, et al.
Published: (2022-05-01) -
Papillary Thyroid Carcinoma with Spindle Cell Metaplasia: A Rare Encounter
by: Ka Wen Leong, et al.
Published: (2022-03-01) -
Aberrant Expression of Androgen Receptor Associated with High Cancer Risk and Extrathyroidal Extension in Papillary Thyroid Carcinoma
by: Chen-Kai Chou, et al.
Published: (2020-04-01) -
<i>ABCA1</i>-Mediated EMT Promotes Papillary Thyroid Cancer Malignancy through the ERK/Fra-1/ZEB1 Pathway
by: Ji-Hye Park, et al.
Published: (2023-01-01) -
CD73 mitigates ZEB1 expression in papillary thyroid carcinoma
by: Samlai Vedovatto, et al.
Published: (2024-02-01)